Ipsos Launches Molecular Diagnostics Monitor in Korea

Ipsos has expanded its Oncology Molecular Diagnostics Monitor to cover Korea, complementing the core Oncology Monitor with data from two panels, one of cancer-treating physicians and the other of pathologists.

The original Oncology Monitor provides an in-depth look at the biomarker testing landscape in the country. The Molecular Diagnostics study has been added after successful launches in the US, EU5, Japan, Australia and China. Respondents are asked to report on how their individual cancer patients and biopsy samples are being tested in the clinical setting, based on de-identified patient and sample record forms. This includes a detailed look at the types of biopsies used, the split by methodology and test brand for each of the biomarkers tested, turn-around time and testing location, as well as the drivers for and barriers to individual biomarker tests.

For the initial wave of the study in Korea, the focus was on non-small cell lung cancer, with other cancer types to be added in future waves of the research. Pieter De Richter, Head of Ipsos' Real World Evidence Portfolio in Asia Pacific and MENA comments: 'The Ipsos Molecular Diagnostics Monitor has allowed us to map the rapid evolution in the oncology biomarker testing landscape in detail, around the world. Pharmaceutical companies and molecular diagnostics manufacturers will now be able to gain a comprehensive insight into how these changes are specifically shaping the South Korean market'.

Web site: www.ipsos.com .

All articles 2006-23 written and edited by Mel Crowther and/or Nick Thomas, 2024- by Nick Thomas, unless otherwise stated.